MedTrace Logo

The Effects of Bromelain Supplement in Patients with Diabetic Foot Ulcers

NCT06786403 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-01-22

No results posted yet for this study

Summary

This study will be conducted on people over 18 with diabetic foot ulcers.. The first group will receive the standard treatment along with bromelain supplement and the second group will receive the standard treatment and placebo. The informed consent form prepared in advance will also be provided to the patients so that they are fully familiar with the study process. Wound surface area, rate of pain, rate of inflammatory factors (ESR and CRP) will be assessed at baseline and every two weeks.

Conditions

  • Diabetic Foot Ulcer (DFU)

Interventions

DIETARY_SUPPLEMENT

Bromelain

Dietary Supplement: Bromelain 1000 mg/day

DIETARY_SUPPLEMENT

Placebo

Placebo (1000 mg/day)

Sponsors & Collaborators

  • Dr Azita Hekmatdoost

    lead OTHER

Principal Investigators

  • Mobina Tajdari, PharmD Student

  • Kamyab Andarzbakhsh, PharmD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2025-08-31
Completion
2025-10-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06786403 on ClinicalTrials.gov